Premium
Intranasal immunization with yeast‐expressed 19 kD carboxyl‐terminal fragment of Plasmodium yoelii merozoite surface protein‐1 (yMSP1 19 ) induces protective immunity to blood stage malaria infection in mice
Author(s) -
HIRUNPETCHARAT CHAKRIT,
STANISIC DANIELLE,
LIU XUE QIN,
VADOLAS JIM,
STRUGNELL RICHARD A.,
LEE ROGAN,
MILLER LOUIS H.,
KASLOW DAVID C.,
GOOD MICHAEL F.
Publication year - 1998
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1046/j.1365-3024.1998.00161.x
Subject(s) - plasmodium yoelii , biology , immunization , antibody , merozoite surface protein , immunity , malaria , nasal administration , virology , immunology , humoral immunity , cholera toxin , malaria vaccine , plasmodium falciparum , immune system , microbiology and biotechnology , parasitemia
Variable protection against malaria blood‐stage infection has been demonstrated in mice following parenteral immunization with the highly conserved 19 kD carboxylterminal fragment of the merozoite surface protein‐1 (MSP1 19 ) using CFA/IFA and other adjuvants. Here we show that intranasal immunization of BALB/C mice with yeast expressed Plasmodium yoelii MSP1 19 plus a mixture of native and recombinant cholera toxin B subunit, could induce serum MSP1 19 ‐specific antibodies at titres ranging from 20 000 to 2 560 000. The Ig subclass responses were predominantly G1 and G2b. Intranasal immunization led to protection following challenge (peak parasitaemia < 1%) in mice with the highest MSP1 19 ‐specific titre (≥ 640 000). In two of the three protected mice, a peak parasitaemia of 0.1%–1% was followed by a boost of the antibody response whereas one of the three protected mice did not boost its antibody response after a peak parasitaemia of 0.02%. In unprotected mice, antibody levels rose, then fell, following the detection of parasites in the peripheral blood. CD4 + T cell‐depletion abrogated the ability of the mice to boost their antibody response following challenge. These data demonstrate the potential for intranasal immunization with MSP1 19 to protect against malaria .